High-dose radioimmunotherapy of B cell lymphomas. 1990

O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
Fred Hutchinson Cancer Research Center, Seattle, Wash.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
September 2007, Clinical cancer research : an official journal of the American Association for Cancer Research,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
July 2012, Cancer control : journal of the Moffitt Cancer Center,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
January 2001, Annals of hematology,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
November 2007, Current opinion in hematology,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
November 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
January 2006, Haematologica,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
January 1993, Medical physics,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
November 2007, Expert opinion on biological therapy,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
June 2007, Cancer research,
O W Press, and J F Eary, and C C Badger, and P J Martin, and F R Appelbaum, and W B Nelp, and K A Krohn, and D Fisher, and B Porter, and E D Thomas
December 2001, Current pharmaceutical biotechnology,
Copied contents to your clipboard!